217 related articles for article (PubMed ID: 2054780)
1. Binding analysis of the estrogen receptor to its specific DNA target site in human breast cancer.
Foster BD; Cavener DR; Parl FF
Cancer Res; 1991 Jul; 51(13):3405-10. PubMed ID: 2054780
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of an estrogen-responsive element binding protein repressed by estradiol.
Gray WG; Gorski J
Biochemistry; 1996 Sep; 35(36):11685-92. PubMed ID: 8794749
[TBL] [Abstract][Full Text] [Related]
3. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
Johnston SR; Lu B; Dowsett M; Liang X; Kaufmann M; Scott GK; Osborne CK; Benz CC
Cancer Res; 1997 Sep; 57(17):3723-7. PubMed ID: 9288779
[TBL] [Abstract][Full Text] [Related]
4. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
5. Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.
Biswas DK; Averboukh L; Sheng S; Martin K; Ewaniuk DS; Jawde TF; Wang F; Pardee AB
Mol Med; 1998 Jul; 4(7):454-67. PubMed ID: 9713824
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
7. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
8. Anti-estrogenic effect of unliganded progesterone receptor is estrogen-selective in breast cancer cells MCF-7.
Zheng ZY; Lin VC
Cancer Lett; 2008 Sep; 268(2):202-11. PubMed ID: 18477500
[TBL] [Abstract][Full Text] [Related]
9. Anti-estrogenic mechanism of unliganded progesterone receptor isoform B in breast cancer cells.
Zheng ZY; Zheng SM; Bay BH; Aw SE; C-L Lin V
Breast Cancer Res Treat; 2008 Jul; 110(1):111-25. PubMed ID: 17687644
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptors alpha and beta exhibit different estradiol and estrogen response element binding in the presence of nonspecific DNA.
Tyulmenkov VV; Klinge CM
Arch Biochem Biophys; 2001 Jun; 390(2):253-64. PubMed ID: 11396928
[TBL] [Abstract][Full Text] [Related]
11. Activation of bone morphogenetic protein-6 gene transcription in MCF-7 cells by estrogen.
Zhang M; Yan JD; Zhang L; Wang Q; Lü SJ; Zhang J; Zhu TH
Chin Med J (Engl); 2005 Oct; 118(19):1629-36. PubMed ID: 16232348
[TBL] [Abstract][Full Text] [Related]
12. Targeting estrogen responsive elements (EREs): design of potent transactivators for ERE-containing genes.
Huang J; Li X; Yi P; Hilf R; Bambara RA; Muyan M
Mol Cell Endocrinol; 2004 Apr; 218(1-2):65-78. PubMed ID: 15130512
[TBL] [Abstract][Full Text] [Related]
13. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity.
Wang LH; Yang XY; Zhang X; Mihalic K; Xiao W; Farrar WL
Cancer Res; 2003 May; 63(9):2046-51. PubMed ID: 12727818
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
15. A HOXA10 estrogen response element (ERE) is differentially regulated by 17 beta-estradiol and diethylstilbestrol (DES).
Akbas GE; Song J; Taylor HS
J Mol Biol; 2004 Jul; 340(5):1013-23. PubMed ID: 15236964
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.
Gionet N; Jansson D; Mader S; Pratt MA
J Cell Biochem; 2009 Jun; 107(3):448-59. PubMed ID: 19350539
[TBL] [Abstract][Full Text] [Related]
17. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
18. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.
Graham ML; Krett NL; Miller LA; Leslie KK; Gordon DF; Wood WM; Wei LL; Horwitz KB
Cancer Res; 1990 Oct; 50(19):6208-17. PubMed ID: 2400987
[TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites.
Petz LN; Ziegler YS; Schultz JR; Kim H; Kemper JK; Nardulli AM
J Steroid Biochem Mol Biol; 2004 Feb; 88(2):113-22. PubMed ID: 15084343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
